Bioheart, Inc.

Bioheart has developed autologous cell therapies such as MyoCell and MyoCell SDF‑1 for chronic heart failure. These therapies aim to improve cardiac function by repopulating scarred regions of the heart with gene-modified muscle cells that secrete additional SDF‑1 protein. Clinical trial results have been presented at major conferences; however, the company has faced financial challenges and regulatory hurdles.[7][8]

Adipocell is a kit-based product using autologous adipose-derived stem cells for various potential applications.[8]

Revenue has declined significantly over recent years as per public filings.[8]

The company was renamed U.S. Stem Cell, Inc., but its legacy programs are still often referred to under the Bioheart name.

There are also unrelated companies named "Bioheart" in China focused on cardiovascular devices rather than cellular therapy; this profile focuses on the US-based biotech entity.